IRIS

Delta-δ-tetrahydrocannabinol and cannabidiol (THC:CBD) oromucosal spray is used as an add-on therapy option for moderate to severe multiple sclerosis (MS) spasticity resistant to other medications. Aims of this study were to provide real-life data on long-term clinical outcomes in a large population of Italian patients treated with THC:CBD and to evaluate predictors of THC:CBD therapy continuation.

Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study / Chisari, Clara Grazia; Solaro, Claudio; Annunziata, Pasquale; Bergamaschi, Roberto; Bianco, Assunta; Bonavita, Simona; Brescia Morra, Vincenzo; Bruno Bossio, Roberto; Capello, Elisabetta; Castelli, Letizia; Cavalla, Paola; Costantino, Gianfranco; Centonze, Diego; Cottone, Salvatore; Danni, Maura Chiara; Esposito, Federica; Gajofatto, Alberto; Gasperini, Claudio; Guareschi, Angelica; Lanzillo, Roberta; Lus, Giacomo; Maniscalco, Giorgia Teresa; Matta, Manuela; Paolicelli, Damiano; Petrucci, Loredana; Pontecorvo, Simona; Righini, Isabella; Rovaris, Marco; Sessa, Edoardo; Spinicci, Gabriella; Spitaleri, Daniele; Valentino, Paola; Zaffaroni, Mauro; Zappia, Mario; Patti, Francesco. - In: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. - ISSN 0022-3050. - (2020), p. jnnp-2019-322480. [10.1136/jnnp-2019-322480]

Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study

Brescia Morra, Vincenzo;Lanzillo, Roberta;
2020

Abstract

Delta-δ-tetrahydrocannabinol and cannabidiol (THC:CBD) oromucosal spray is used as an add-on therapy option for moderate to severe multiple sclerosis (MS) spasticity resistant to other medications. Aims of this study were to provide real-life data on long-term clinical outcomes in a large population of Italian patients treated with THC:CBD and to evaluate predictors of THC:CBD therapy continuation.
2020
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study / Chisari, Clara Grazia; Solaro, Claudio; Annunziata, Pasquale; Bergamaschi, Roberto; Bianco, Assunta; Bonavita, Simona; Brescia Morra, Vincenzo; Bruno Bossio, Roberto; Capello, Elisabetta; Castelli, Letizia; Cavalla, Paola; Costantino, Gianfranco; Centonze, Diego; Cottone, Salvatore; Danni, Maura Chiara; Esposito, Federica; Gajofatto, Alberto; Gasperini, Claudio; Guareschi, Angelica; Lanzillo, Roberta; Lus, Giacomo; Maniscalco, Giorgia Teresa; Matta, Manuela; Paolicelli, Damiano; Petrucci, Loredana; Pontecorvo, Simona; Righini, Isabella; Rovaris, Marco; Sessa, Edoardo; Spinicci, Gabriella; Spitaleri, Daniele; Valentino, Paola; Zaffaroni, Mauro; Zappia, Mario; Patti, Francesco. - In: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. - ISSN 0022-3050. - (2020), p. jnnp-2019-322480. [10.1136/jnnp-2019-322480]
1.1 Articolo in rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/814024
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact